We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+35.52%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$376M
AUM Growth
+$68.7M
Cap. Flow
+$6.54M
Cap. Flow %
1.74%
Top 10 Hldgs %
62.6%
Holding
53
New
13
Increased
11
Reduced
14
Closed
8

Top Buys

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$10.8M
2
ARVN icon
Arvinas
ARVN
+$6.16M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$5.33M
4
CDXS icon
Codexis
CDXS
+$4.14M
5
TGTX icon
TG Therapeutics
TGTX
+$3.78M

Top Sells

Rank Stock Value
1
MOR
MorphoSys AG American Depositary Shares
MOR
+$7.82M
2
BHVN icon
Biohaven
BHVN
+$7.43M
3
TELA icon
TELA Bio
TELA
+$6M
4
GERN icon
Geron
GERN
+$4.06M
5
KALV
KalVista Pharmaceuticals
KALV
+$3.18M

Sector Composition

Rank Sector Weight
1 Healthcare 99.22%
2 Miscellaneous 0.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDSX icon
26
Biodesix
BDSX
$300M
$3.61M 0.96%
24,825
+2,046
+9% +$64.2K
TRVI icon
27
Trevi Therapeutics
TRVI
$2.56B
$3.4M 0.9%
2,535,000
+829,100
+49% +$1.26M
JSPR icon
28
Jasper Therapeutics
JSPR
$23.3M
$3.14M 0.84%
+398,534
New +$2.67M
NTLA icon
29
Intellia Therapeutics
NTLA
$1.84B
$3.02M 0.8%
+99,000
New +$2.85M
NAMS icon
30
NewAmsterdam Pharma
NAMS
$3.2B
$2.96M 0.79%
+265,388
New +$2.43M
LRMR icon
31
Larimar Therapeutics
LRMR
$421M
$2.84M 0.75%
623,500
-225,000
-27% -$759K
VTYX
32
DELISTED
Ventyx Biosciences
VTYX
$2.82M 0.75%
+1,140,000
New +$10.8M
SYRS
33
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.8M 0.74%
+359,370
New +$1.23M
GOSS icon
34
Gossamer Bio
GOSS
$83.2M
$2.72M 0.72%
2,982,200
-1,772,000
-37% -$1.31M
PTGX icon
35
Protagonist Therapeutics
PTGX
$9.67B
$2.58M 0.69%
+112,700
New +$1.97M
KALV
36
DELISTED
KalVista Pharmaceuticals
KALV
$1.84M 0.49%
150,000
-350,000
-70% -$3.18M
VSTM icon
37
Verastem
VSTM
$668M
$1.72M 0.46%
211,400
– –
NYXH
38
Nyxoah
NYXH
$160M
$1.6M 0.43%
344,800
-97,096
-22% -$533K
MOR
39
DELISTED
MorphoSys AG American Depositary Shares
MOR
$1.44M 0.38%
145,000
-1,064,380
-88% -$7.82M
PGEN icon
40
Precigen
PGEN
$2.57B
$1.36M 0.36%
1,012,500
+84,000
+9% +$98.7K
STRO icon
41
Sutro Biopharma
STRO
$353M
$1.29M 0.34%
+30,149
New +$957K
CNTX icon
42
Context Therapeutics
CNTX
$38.2M
$1.1M 0.29%
+975,000
New +$1.05M
FULC icon
43
Fulcrum Therapeutics
FULC
$294M
$878K 0.23%
+130,000
New +$577K
ALGS icon
44
Aligos Therapeutics
ALGS
$44.1M
$861K 0.23%
+51,880
New +$892K
KNSA icon
45
Kiniksa Pharmaceuticals
KNSA
$6.23B
$640K 0.17%
+37,500
New +$616K
FBIO icon
46
Fortress Biotech
FBIO
$93.4M
– –
-133,333
Closed -$581K
GERN icon
47
Geron
GERN
$983M
– –
-1,915,000
Closed -$4.06M
IGMS
48
DELISTED
IGM Biosciences
IGMS
– –
-261,000
Closed -$2.18M
KZR
49
DELISTED
Kezar Life Sciences
KZR
– –
-42,500
Closed -$506K
TELA icon
50
TELA Bio
TELA
$29.2M
– –
-750,000
Closed -$6M
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2023 Portfolio in Review

As of Q4 2023, Opaleye Management held 53 positions worth $376M, up 22% from $307M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Opaleye Management's Q4 2023 filing shows 13 new, 11 increased, 14 reduced and 8 closed positions. Its largest new stake was Ventyx Biosciences: 1,140,000 shares worth $2.82M. The largest sale was MorphoSys AG American Depositary Shares, an estimated $7.82M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q4 2023 buy was Ventyx Biosciences: 1,140,000 shares worth $2.82M.
  • Opaleye Management added most to Codexis in Q4 2023, an estimated $4.14M increase.
  • Opaleye Management's biggest Q4 2023 reduction was MorphoSys AG American Depositary Shares, cutting an estimated $7.82M.
  • Opaleye Management fully exited TELA Bio in Q4 2023, selling an estimated $6M.
  • Opaleye Management's ten largest holdings make up 63% of its $376M portfolio in Q4 2023.
  • Opaleye Management opened 13 new positions and closed 8 in Q4 2023.
  • Opaleye Management's portfolio value rose 22% quarter-over-quarter to $376M.

Based on Opaleye Management's 13F filing for Q4 2023, filed 14 Feb 2024.